![Robert A. Doody](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert A. Doody
Investor Relations Kontakt bei
PRELUDE THERAPEUTICS INCORPORATED
Profil
Robert A. Doody is Senior Vice President-Investor Relations at Prelude Therapeutics, Inc. since 2024.
Formerly, Mr. Doody was Assistant Director-Investor Relations at Shire ViroPharma, Inc. from 2012 to 2014.
Mr. Doody served as Vice President-Investor Relations at Provention Bio, Inc. from 2021 to 2022.
Mr. Doody held positions as VP-Investor Relations & Corporate Communications at Idera Pharmaceuticals, Inc. and Senior Vice President-Investor Relations at Aclaris Therapeutics, Inc. Mr. Doody completed undergraduate studies at Rowan University in 2002.
Aktive Positionen von Robert A. Doody
| Unternehmen | Position | Beginn |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Kontakt | 01.01.2024 |
Ehemalige bekannte Positionen von Robert A. Doody
| Unternehmen | Position | Ende |
|---|---|---|
| PROVENTION BIO, INC. | Investor Relations Kontakt | 01.09.2022 |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Public Communications Contact | 01.01.2014 |
| ACLARIS THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Investor Relations Kontakt | - |
Ausbildung von Robert A. Doody
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
62
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Rowan University
 Rowan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company that engages in intercepting and preventing immune-mediated diseases including type 1 diabetic activities | Health Technology |
